Related references
Note: Only part of the references are listed.Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Gail J. Roboz et al.
BLOOD ADVANCES (2018)
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
May Daher et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
Theo de Witte et al.
BLOOD (2017)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies
Margriet Oosterveld et al.
ANNALS OF HEMATOLOGY (2015)
Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia
Alison R. Walker et al.
LEUKEMIA & LYMPHOMA (2014)
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432
Harry P. Erba et al.
LEUKEMIA RESEARCH (2014)
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
Luca Malcovati et al.
BLOOD (2013)
Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
William Blum et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
Elias Jabbour et al.
CANCER (2011)
A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias
Jeffrey E. Lancet et al.
CLINICAL CANCER RESEARCH (2011)
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes
Giuliana Alimena et al.
LEUKEMIA RESEARCH (2011)
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes
Ebenezer David et al.
BLOOD (2010)
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older
Jean-Luc Harousseau et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
Mohamed L. Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A multicenter phase 2 study of the famesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
Pierre Fenaux et al.
BLOOD (2007)
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D. Cheson et al.
BLOOD (2006)
Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia
N Yanamandra et al.
CLINICAL CANCER RESEARCH (2006)
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
R Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes:: delayed transplantation for low-risk myelodysplasia is associated with improved outcome
CS Cutler et al.
BLOOD (2004)
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
R Kurzrock et al.
BLOOD (2003)
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer
M Crul et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
